Check Before You Invest : Emcure Pharmaceuticals Ltd

Snapshot

Q.1 Which industry/sub-sector does Emcure Pharmaceuticals Ltd belong to?

Emcure Pharmaceuticals Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.2 Is Emcure Pharmaceuticals Ltd a good quality company?

Emcure Pharmaceuticals Ltd is a good quality company, based on a consistently good 10-year financial track record.

Q.3 Is Emcure Pharmaceuticals Ltd undervalued or overvalued?

Emcure Pharmaceuticals Ltd appears Somewhat overvalued, as its key valuation ratios are above with their past averages.

Q.4 Is Emcure Pharmaceuticals Ltd a good buy now?

Emcure Pharmaceuticals Ltd is a good buy now, based on strong price trend analysis suggesting prices may rise. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Emcure Pharmaceuticals Ltd?

Emcure Pharmaceuticals Ltd revenue growth is 25.3% for FY-2025, which is above its 5-year CAGR of 13.02%, indicating faster growth.

Q.2 Return on capital employed (ROCE) of Emcure Pharmaceuticals Ltd?

Emcure Pharmaceuticals Ltd Return on capital employed is 15.4% for FY-2025, which is in line with its 5-year historical median of 15.4%. The current ROCE is above its estimated weighted average cost of capital (WACC) of 13.5%, indicating value creation.

Q.3 Return on Asset of Emcure Pharmaceuticals Ltd?

Emcure Pharmaceuticals Ltd Return on Asset is 6.23%, which is in line with its 5-year historical median of 6.23%, indicating stable asset utilization efficiency.

Q.4 Return on Equity (ROE) of Emcure Pharmaceuticals Ltd?

Emcure Pharmaceuticals Ltd Return on equity is 12.86% for FY-2025, which is in line with its 5-year historical median of 12.86%, indicating the business is making similar use of its shareholders capital.

Q.5 Cash conversion cycle of Emcure Pharmaceuticals Ltd?

Emcure Pharmaceuticals Ltd Cash conversion cycle is 76 days, below its 5-year historical median of 95 days, indicating improved working capital management. However, you need to compare this with its peers in the industry.

	Current Level	5-year Historic Median
Asset Turnover	0.86	0.75
ROE	12.86	12.86
ROCE	15.4	15.4
Cash Conversion Cycle	76 days	95 days

Q.6 Gross Profit margin of Emcure Pharmaceuticals Ltd?

Emcure Pharmaceuticals Ltd Gross profit margin which is the profit after deduction of direct costs, is 14.9% for FY-2025, which is in line with its 5-year median of 14.9%, indicating stable margins.

Q.7 Operating Profit Margin of Emcure Pharmaceuticals Ltd?

Emcure Pharmaceuticals Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 14.22% for FY-2025, which is in line with its 5-year median of 14.22% indicating stable margins.

Q.8 Net Profit Margin of Emcure Pharmaceuticals Ltd?

Emcure Pharmaceuticals Ltd Net Profit Margin is 7.24% for FY-2025, is in line with with its 5-year median of 7.24%, indicating stable margins.

	Current Level	5-year Historic Median
Gross Profit Margin	14.9	14.9
Operating Profit Margin	14.22	14.22
Net Profit Margin	7.24	7.24

Q.9 Debt to Equity ratio of Emcure Pharmaceuticals Ltd?

Emcure Pharmaceuticals Ltd Debt-to-Equity ratio is 0.22, which is lower with the industry average of 0.27, indicating lower debt levels in the industry.

Q.10 Debt to cash flow from operations of Emcure Pharmaceuticals Ltd?

Emcure Pharmaceuticals Ltd Debt to cash flow from operations is 1.17, which is at a healthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Emcure Pharmaceuticals Ltd?

Promoters hold 77.87% of the Emcure Pharmaceuticals Ltd, with 0.04% of their stake pledged, indicating low pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Emcure Pharmaceuticals Ltd vs industry peers?

Emcure Pharmaceuticals Ltd revenue CAGR is 13.02%, compared to the industry median CAGR of 8.30%, indicating faster growth and gaining its market share.

Profit Metrics

	Current Level	5-year Industry Median
Revenue Growth	25.3	8.3
Gross Profit Growth	57.7	14.7
Operating Profit Growth	41	11.4
Net Profit Growth	96.9	NAN

Operating Efficiency

	Current Level	5-year Industry Median
Asset Turnover	0.86	0.81
ROE	12.86	9.49
ROCE	15.4	11.91
Cash Conversion Cycle (days)	76.07	85

Valuation & price assessment

Q.1 Stock return of Emcure Pharmaceuticals Ltd over the last decade?

Over the last 1 year(s), the stock has delivered a CAGR of 59.45% based on the current price.

Q.2 What return has the stock given over the last decade?

	9Y	5Y	3Y	1Y
Share Price CAGR	-	-	-	59.5%

Q.3 Valuation ratios of Emcure Pharmaceuticals Ltd vs historical?

The current P/E is lower that its historical median.

Q.4 How do the current valuation ratios compare with 5-year historical median and industry numbers?

Valuation Ratios	Current	5-year Historic Median	5-year Industry Median
Price to Earnings	43.75	108.67	31.09
Price to Book	9.24	8.15	2.85
Price to Sales	6.12	5.95	2.79
EV to EBITDA	25.05	34.06	15.87

Check more companies

5. Wockhardt

8. Pfizer

10. Neuland Laboratories

Check trending companies

1. Yes Bank Ltd.

2. RBL Bank Ltd.

3. Samvardhana Motherson International Ltd.

4. Jindal Saw Ltd.

5. Union Bank Of India